RVMD

MKT CAP:$28B

Revolution Medicines, Inc.

Market Cap

$28B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$136.08+$57.06 (+72.21%)

Apr 24, 2026

Company Details

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 cl...

CEO

Mark A. Goldsmith

IPO Date

Feb 13, 2020

Website

www.revmed.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$1.1B

EPS (Diluted)

-$5.95

Free Cash Flow

-$914M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 6, 2026

PENDING

FY 2025

Feb 25, 2026

$0EPS -$5.95

Q4 2025

Feb 25, 2026

$0EPS -$1.90

Q3 2025

Nov 5, 2025

$0EPS -$1.61

Q2 2025

Aug 6, 2025

$0EPS -$1.31

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$8M	$8M	-$58M
Q2 22	$9M	$9M	-$62M
Q3 22	$3M	$3M	-$77M
Q4 22	$15M	$15M	-$62M
Q1 23	$7M	$7M	-$75M
Q2 23	$4M	$4M	-$109M
Q3 23	$0	$0	-$123M
Q4 23	$742.0K	$742.0K	-$180M
Q1 24	$0	$0	-$141M
Q2 24	$0	$0	-$157M
Q3 24	$0	$0	-$176M
Q4 24	$0	$0	-$216M
Q1 25	$0	$0	-$241M
Q2 25	$0	$0	-$265M
Q3 25	$0	$0	-$315M
Q4 25	$0	-$5M	-$362M

Valuation

Quarter	P/S	P/E
Q1 22	68.2x	—
Q2 22	50.4x	—
Q3 22	59.0x	—
Q4 22	59.3x	—
Q1 23	65.3x	—
Q2 23	99.3x	—
Q3 23	141.2x	—
Q4 23	417.2x	—
Q1 24	1145.8x	—
Q2 24	8726.7x	—
Q3 24	10251.9x	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$55M	-$57M
Q2 22	-$56M	-$58M
Q3 22	-$52M	-$55M
Q4 22	-$62M	-$65M
Q1 23	-$62M	-$64M
Q2 23	-$67M	-$68M
Q3 23	-$100M	-$103M
Q4 23	-$121M	-$123M
Q1 24	-$161M	-$164M
Q2 24	-$128M	-$131M
Q3 24	-$130M	-$134M
Q4 24	-$138M	-$140M
Q1 25	-$194M	-$198M
Q2 25	-$222M	-$229M
Q3 25	-$207M	-$211M
Q4 25	-$274M	-$276M

Capital Expenditures

Quarter	CapEx
Q1 22	$2M
Q2 22	$3M
Q3 22	$4M
Q4 22	$3M
Q1 23	$2M
Q2 23	$1M
Q3 23	$3M
Q4 23	$2M
Q1 24	$3M
Q2 24	$2M
Q3 24	$4M
Q4 24	$1M
Q1 25	$3M
Q2 25	$7M
Q3 25	$3M
Q4 25	$2M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-25.2%	+37.9%
Q2 22	+4.8%	+33.8%
Q3 22	+204.8%	+47.2%
Q4 22	+62.1%	+23.5%
Q1 23	-7.4%	+25.4%
Q2 23	-58.1%	+58.2%
Q3 23	-100.0%	+54.3%
Q4 23	-95.2%	+134.6%
Q1 24	-100.0%	+71.4%
Q2 24	-100.0%	+39.1%
Q3 24	—	+42.6%
Q4 24	-100.0%	+19.7%
Q1 25	—	+70.9%
Q2 25	—	+69.0%
Q3 25	—	+79.4%
Q4 25	—	+67.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$7M	87.7%
Q2 22	$8M	88.8%
Q3 22	$8M	242.5%
Q4 22	$8M	54.2%
Q1 23	$10M	138.3%
Q2 23	$13M	339.4%
Q3 23	$14M	—
Q4 23	$25M	3426.8%
Q1 24	$16M	—
Q2 24	$20M	—
Q3 24	$21M	—
Q4 24	$22M	—
Q1 25	$25M	—
Q2 25	$29M	—
Q3 25	$31M	—
Q4 25	$34M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$56M	$9M
Q2 22	$61M	$10M
Q3 22	$69M	$10M
Q4 22	$66M	$11M
Q1 23	$69M	$13M
Q2 23	$98M	$15M
Q3 23	$108M	$16M
Q4 23	$148M	$32M
Q1 24	$118M	$23M
Q2 24	$135M	$22M
Q3 24	$152M	$24M
Q4 24	$188M	$28M
Q1 25	$206M	$35M
Q2 25	$224M	$41M
Q3 25	$263M	$53M
Q4 25	$293M	$64M

Revenue Segments

Quarter	Collaboration Revenue	Collaboration Revenue Member
Q1 22	$8M	—
Q2 22	—	$9M
Q3 22	—	$3M
Q4 22	—	$15M
Q1 23	—	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$98M	$421M	$519M
Q2 22	$106M	$356M	$461M
Q3 22	$179M	$476M	$655M
Q4 22	$161M	$484M	$645M
Q1 23	$427M	$483M	$910M
Q2 23	$380M	$529M	$909M
Q3 23	$358M	$455M	$813M
Q4 23	$696M	$1.2B	$1.9B
Q1 24	$288M	$1.4B	$1.7B
Q2 24	$276M	$1.3B	$1.6B
Q3 24	$201M	$1.3B	$1.5B
Q4 24	$543M	$1.7B	$2.3B
Q1 25	$334M	$1.8B	$2.1B
Q2 25	$402M	$1.7B	$2.1B
Q3 25	$217M	$1.7B	$1.9B
Q4 25	$384M	$1.6B	$2.0B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	74M	+0.4%	+5.3%
Q2 22	74M	+0.2%	+1.2%
Q3 22	85M	+14.0%	+15.2%
Q4 22	89M	+5.3%	+20.8%
Q1 23	95M	+6.4%	+27.9%
Q2 23	107M	+12.7%	+43.9%
Q3 23	109M	+2.2%	+29.0%
Q4 23	141M	+29.3%	+58.4%
Q1 24	165M	+16.7%	+73.7%
Q2 24	165M	+0.3%	+54.5%
Q3 24	167M	+1.0%	+52.7%
Q4 24	168M	+0.5%	+18.8%
Q1 25	188M	+12.2%	+14.2%
Q2 25	188M	-0.0%	+13.9%
Q3 25	189M	+0.6%	+13.4%
Q4 25	190M	+0.5%	+13.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$40.3K	188
Q2 22	$48.5K	188
Q3 22	$17.9K	188
Q4 22	$62.3K	246
Q1 23	$28.5K	246
Q2 23	$15.5K	246
Q3 23	$0	246
Q4 23	$2.0K	378
Q1 24	$0	378
Q2 24	$0	378
Q3 24	$0	378
Q4 24	$0	534
Q1 25	$0	534
Q2 25	$0	534
Q3 25	$0	534
Q4 25	$0	200K

Revenue / Employee